3 unknown. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
| Phase 3 | 1 | Unknown 1 |
Follow Blindness: new trials by email Literature Review of Blindness trials Research Report on Blindness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1 Tirzepatide - Wolfram Syndrome | Phase 2 | Unknown | Ospedale San Raffaele | 10 | 2024-01-01 | 2024-02-22 |
| Efficacy Study of Daily Administration of VPA in Patients Affected by Wolfram Syndrome Depakine - Wolfram Syndrome | Phase 2 | Unknown | Centre d'Etude des Cellules Souches | 23 | 2021-11-26 | 2023-11-28 |
| An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. sepofarsen - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Unknown | ProQR Therapeutics | 15 | 2021-03-23 | 2022-03-25 |
Wolfram Syndrome (2) · Diabetes Mellitus (1) · Eye Abnormalities (1) · Eye Diseases (1) · Leber Congenital Amaurosis (1) · Leber Congenital Amaurosis 10 (1) · Meckel Syndrome, Type 4 (1) · Neurologic Manifestations (1) · Retinal Degeneration (1) · Retinal Diseases (1) · Retinal Dystrophies (1) · Sensation Disorders (1) · Vision Disorders (1)
Congenital Abnormalities (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Eye Diseases, Hereditary (3) · Nervous System Diseases (3) · Abnormalities, Multiple (2) · Cranial Nerve Diseases (2) · Deaf-Blind Disorders (2) · Deafness (2) · Diabetes Insipidus (2) · Diabetes Mellitus, Type 1 (2) · Ear Diseases (2) · Endocrine System Diseases (2) · Eye Diseases (2) · Female Urogenital Diseases (2)
Tirzepatide (1) · Valproic Acid (1)
Centre d'Etude des Cellules Souches (1) · Ospedale San Raffaele (1) · ProQR Therapeutics (1)
Italy (2) · Belgium (1) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Netherlands (1) · Spain (1) · United Kingdom (1)